MARKET

ENLV

ENLV

Enlivex Therapeutics Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.960
-0.070
-1.74%
Closed 16:00 05/18 EDT
OPEN
3.920
PREV CLOSE
4.030
HIGH
4.100
LOW
3.770
VOLUME
32.25K
TURNOVER
30.97K
52 WEEK HIGH
13.95
52 WEEK LOW
3.650
MARKET CAP
72.76M
P/E (TTM)
-4.8925
1D
5D
1M
3M
1Y
5Y
Enlivex Announces Upcoming May Conference Presentations
Nes-Ziona, Israel, May 10, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will be presenting scientific and clinical...
GlobeNewswire · 05/10 12:00
Enlivex Presented Substantial Survival Benefit of Allocetra in Combination with Immune Checkpoint Inhibitor in Mesothelioma Cancer Study at the International Society for Cell and Gene Therapy Annual 2022 Meeting
chart - click to enlarge AB-137 study: survival and complete cure results Mesothelioma is one of the deadliest solid cancers, with few treatment options, all of which have limited efficacy. Immune checkpoint inhibitors targeting CTLA4 and PD1 are FDA-appro...
GlobeNewswire · 05/09 13:05
Enlivex gets 2 US patents for treating sepsis with cell therapy Allocetra
Enlivex Therapeutics (NASDAQ:ENLV) said it was issued two U.S. patents related to claims covering methods of treating sepsis with Allocetra. The company noted that U.S. Patent No. 11,304,976 and 11,318,163, each
Seekingalpha · 05/05 13:25
Enlivex Announces Issuance Of Two U.S. Patents Covering Methods Of Treating Sepsis With Allocetra
Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the ", Company", )))), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of U.S. Patent Nos. 11,304,976 and 11,318,163. Each
Benzinga · 05/05 12:38
Enlivex Announces Issuance of Two U.S. Patents Covering Methods of Treating Sepsis with Allocetra
Nes-Ziona, Israel, May 05, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of U.S. Patent Nos. 11,304,976 and 11,318,163. Each p...
GlobeNewswire · 05/05 12:37
Enlivex Therapeutics Highlights Will Present Poster at American Society Of Clinical Oncology Meeting Jun. 5, 2022 At 9 a.m. EDT
Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the &ldquo, Company&rdquo, )), a clinical-stage macrophage reprogramming immunotherapy company, today announced the acceptance of an abstract for a poster presentation at the
Benzinga · 05/02 12:17
Enlivex Announces Upcoming Poster Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
Nes-Ziona, Israel, May 02, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the acceptance of an abstract for a poster presentation at the upc...
GlobeNewswire · 05/02 12:00
--HC Wainwright Adjusts Enlivex Therapeutics' Price Target to $15 from $33, Keeps Buy Rating
MT Newswires · 05/02 08:24
More
No Data
Learn about the latest financial forecast of ENLV. Analyze the recent business situations of Enlivex Therapeutics Ltd through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ENLV stock price target is 15.00 with a high estimate of 15.00 and a low estimate of 15.00.
High15.00
Average15.00
Low15.00
Current 3.960
EPS
Actual
Estimate
-0.39-0.34-0.30-0.26
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 29
Institutional Holdings: 822.67K
% Owned: 4.48%
Shares Outstanding: 18.37M
TypeInstitutionsShares
Increased
2
92.03K
New
2
15.63K
Decreased
1
59
Sold Out
2
30.13K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.24%
Pharmaceuticals & Medical Research
-2.06%
Key Executives
Chief Executive Officer
Oren Hershkovitz
Vice Chairman/Executive Director/Director
Shai Novik
Founder/Chief Scientific Officer
Dror Mevorach
Chief Financial Officer
Shachar Shlosberger
Director
Baruch Halpert
Director
Bernhard Kirschbaum
Director
Sangwoo Lee
Director
Brian Schwartz
Independent Director
Michel Habib
Independent Director
Gili Hart
Independent Director
Abraham Havron
No Data
No Data
About ENLV
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

Webull offers kinds of Enlivex Therapeutics Ltd stock information, including NASDAQ:ENLV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENLV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ENLV stock methods without spending real money on the virtual paper trading platform.